Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mikko Neuvonen

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Clinical Pharmacology and Therapeutics|June 18, 2005
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokineticsMikko Niemi, Janne T Backman, Lauri I Kajosaari, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 2024
Candesartan Has No Clinically Meaningful Effect on the Plasma Concentrations of Cytochrome P450 2C8 Substrate Repaglinide in HumansMikael O W Piha, Kristiina Cajanus, Marica T Engström, et al.
BJA Open|August 17, 2023
Circulating oxylipin and bile acid profiles of dexmedetomidine, propofol, sevoflurane, and S-ketamine: a randomised controlled trial using tandem mass spectrometryAleksi Nummela, Lauri Laaksonen, Annalotta Scheinin, et al.
Clinical Pharmacokinetics|October 23, 2024
Population Pharmacokinetic Quantification of CYP2D6 Activity in Codeine Metabolism in Ambulatory Surgical Patients for Model-Informed Precision DosingMuhammad Waqar Ashraf, Satu Poikola, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|October 3, 2023
Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate RosuvastatinMinna Lehtisalo, E Katriina Tarkiainen, Mikko Neuvonen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 23, 2021
An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivityHelinä Kahma, Laura Aurinsalo, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|June 2, 2022
Genomewide Association Study of Simvastatin PharmacokineticsAnssi J H Mykkänen, Suvi Taskinen, Mikko Neuvonen, et al.
Journal of Veterinary Internal Medicine|January 19, 2023
Extraesophageal reflux and reflux aspiration in dogs with respiratory diseases and in healthy dogsSirkku Kouki, Sanna J Viitanen, Ninna Koho, et al.
British Journal of Clinical Pharmacology|October 23, 2023
Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatmentAleksi M Olkkola, Tuija Tapaninen, Aleksi Tornio, et al.
Clinical Pharmacology and Therapeutics|March 3, 2025
Identification of Genetic Variants Associated with Pravastatin and Pitavastatin PharmacokineticsAnssi J H Mykkänen, E Katriina Tarkiainen, Suvi Taskinen, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Clinical Pharmacology and Therapeutics|June 18, 2005
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokineticsMikko Niemi, Janne T Backman, Lauri I Kajosaari, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 2024
Candesartan Has No Clinically Meaningful Effect on the Plasma Concentrations of Cytochrome P450 2C8 Substrate Repaglinide in HumansMikael O W Piha, Kristiina Cajanus, Marica T Engström, et al.
BJA Open|August 17, 2023
Circulating oxylipin and bile acid profiles of dexmedetomidine, propofol, sevoflurane, and S-ketamine: a randomised controlled trial using tandem mass spectrometryAleksi Nummela, Lauri Laaksonen, Annalotta Scheinin, et al.
Clinical Pharmacokinetics|October 23, 2024
Population Pharmacokinetic Quantification of CYP2D6 Activity in Codeine Metabolism in Ambulatory Surgical Patients for Model-Informed Precision DosingMuhammad Waqar Ashraf, Satu Poikola, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|October 3, 2023
Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate RosuvastatinMinna Lehtisalo, E Katriina Tarkiainen, Mikko Neuvonen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 23, 2021
An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivityHelinä Kahma, Laura Aurinsalo, Mikko Neuvonen, et al.
Clinical Pharmacology and Therapeutics|June 2, 2022
Genomewide Association Study of Simvastatin PharmacokineticsAnssi J H Mykkänen, Suvi Taskinen, Mikko Neuvonen, et al.
Journal of Veterinary Internal Medicine|January 19, 2023
Extraesophageal reflux and reflux aspiration in dogs with respiratory diseases and in healthy dogsSirkku Kouki, Sanna J Viitanen, Ninna Koho, et al.
British Journal of Clinical Pharmacology|October 23, 2023
Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatmentAleksi M Olkkola, Tuija Tapaninen, Aleksi Tornio, et al.
Clinical Pharmacology and Therapeutics|March 3, 2025
Identification of Genetic Variants Associated with Pravastatin and Pitavastatin PharmacokineticsAnssi J H Mykkänen, E Katriina Tarkiainen, Suvi Taskinen, et al.
Pageof 11